%0 Journal Article
%A Garcia-Cervera, Carles
%A Giner-Galvañ, Vicente
%A Wikman-Jorgensen, Philip
%A Laureiro, Jaime
%A Rubio-Rivas, Manuel
%A Gurjian-Arena, Anthony
%A Arnalich-Fernandez, Francisco
%A Beato-Perez, Jose Luis
%A Vargas-Nuñez, Juan Antonio
%A Gonzalez-Igual, Jesus Javier
%A Diez-Manglano, Jesus
%A Mendez-Bailon, Manuel
%A Garcia-Blanco, Maria Jose
%A Freire-Castro, Santiago J
%A Aranda-Lobo, Judit
%A Manzano, Luis
%A Magallanes-Gamboa, Jeffrey Oskar
%A Arribas-Perez, Luis
%A Gonzalez-Moraleja, Julio
%A Calderon-Hernaiz, Ruth
%A Garcia-Alegria, Javier
%A Gonzalez-Noya, Amara
%A Gomez-Huelgas, Ricardo
%A Lumbreras-Bermejo, Carlos
%A Anton-Santos, Juan Miguel
%T Estimation of Admission D-dimer Cut-off Value to Predict Venous Thrombotic Events in Hospitalized COVID-19 Patients: Analysis of the SEMI-COVID-19 Registry.
%D 2021
%U http://hdl.handle.net/10668/18231
%X Venous thrombotic events (VTE) are frequent in COVID-19, and elevated plasma D-dimer (pDd) and dyspnea are common in both entities. To determine the admission pDd cut-off value associated with in-hospital VTE in patients with COVID-19. Multicenter, retrospective study analyzing the at-admission pDd cut-off value to predict VTE and anticoagulation intensity along hospitalization due to COVID-19. Among 9386 patients, 2.2% had VTE: 1.6% pulmonary embolism (PE), 0.4% deep vein thrombosis (DVT), and 0.2% both. Those with VTE had a higher prevalence of tachypnea (42.9% vs. 31.1%; p = 0.0005), basal O2 saturation 1.0 μg/ml treated with prophylactic dose (p 2.0 μg/ml treated with intermediate dose (p = 0.0001), and 31.3% for those with pDd >3.0 μg/ml and full anticoagulation (p = 0.0183). In hospitalized patients with COVID-19, a pDd value greater than 3.0 μg/ml can be considered to screen VTE and to consider full-dose anticoagulation.
%K COVID-19
%K D-dimer
%K SARS-CoV-2
%K Deep vein thrombosis
%K Pulmonary embolism
%K Venous thrombotic event
%~